HspX protein as a candidate vaccine against Mycobacterium tuberculosis: an overview

Abstract

BACKGROUND: Tuberculosis (TB) is a contagious infectious disease caused by Mycobacterium tuberculosis (Mtb). This disease with two million deaths per year has the highest mortality rate among bacterial infections. The only available vaccine against TB is BCG vaccine. BCG is an effective vaccine against TB in childhood, however, due to some limitations, has not proper efficiency in adults. Also, BCG cannot produce an adequately protective response against reactivation of latent infections.

OBJECTIVE: In the present study we will review the most recent findings about contribution of HspX protein in the vaccines against tuberculosis.

METHODS: Therefore, many attempts have been made to improve BCG or to find its replacement. Most of the subunit vaccines for TB in various phases of clinical trials were constructed as prophylactic vaccines using Mtb proteins expressed in the replicating stage. These vaccines might prevent active TB but not reactivation of latent tuberculosis infection (LTBI). A literature search was performed on various online databases (PubMed, Scopus, and Google Scholar) regarding the roles of HspX protein in tuberculosis vaccines.

RESULTS: Ideal subunit post-exposure vaccines should target all forms of TB infection, including active symptomatic and dormant (latent) asymptomatic forms. Among these subunit vaccines, HspX is the most important latent phase antigen of M. tuberculosis with a strong immunological response. There are many studies that have evaluated the immunogenicity of this protein to improve TB vaccine.

CONCLUSION: According to the studies, HspX protein is a good candidate for development of subunit vaccines against TB infection.

Key words： HspX protein; Mycobacterium tuberculosis; vaccine

Acknowledgements

The authors are grateful to our colleagues in Mashhad University of Medical Sciences for their sincerely cooperation.

Compliance with ethics guidelines

Authors declare that they have no conflict of interest. This article does not contain any studies with human or animal subjects performed by any of the authors.

References

1 Aagaard C, Dietrich J, Doherty M, Andersen P (2009). TB vaccines: current status and future perspectives. Immunol Cell Biol, 87(4): 279–286

PMID

2 Andersen P, Kaufmann S H (2014). Novel vaccination strategies against tuberculosis. Cold Spring HarbPerspect Med, 4(6): a018523

PMID

3 Britton W J, Palendira U (2003). Improving vaccines against tuberculosis. Immunol Cell Biol, 81(1): 34–45

PMID

4 Chen L, Xu M, Wang Z Y, Chen B W, Du W X, Su C, Shen X B, Zhao A H, Dong N, Wang Y J, Wang G Z (2010). The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants. FEMS Immunol Med Microbiol, 59(1): 42–52

PMID

5 da Costa A C, Costa-Júnior A O, de Oliveira F M, Nogueira S V, Rosa J D, Resende D P, Kipnis A, Junqueira-Kipnis A P (2014). A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis. PLoS One, 9(11): e112848

PMID

6 de Sousa E M, da Costa A C, Trentini M M, de AraújoFilho J A, Kipnis A, Junqueira-Kipnis A P (2012). Immunogenicity of a fusion protein containing immunodominant epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in mice and active TB infection. PLoS One, 7(10): e47781

PMID

7 Geluk A, Lin M Y, van Meijgaarden K E, Leyten E M, Franken K L, Ottenhoff T H, Klein M R (2007). T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect Immun, 75(6): 2914–2921

PMID

8 Jeon B Y, Kim S C, Eum S Y, Cho S N (2011). The immunity and protective effects of antigen 85A and heat-shock protein X against progressive tuberculosis. Microbes Infect, 13(3): 284–290

PMID

9 Jung I D, Shin S J, Lee M G, Kang T H, Han H D, Lee S J, Kim W S, Kim H M, Park W S, Kim H W, Yun C H, Lee E K, Wu T C, Park Y M (2014). Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X. J Immunol, 193(3): 1233–1245

PMID

10 Junqueira-Kipnis A P, Marques Neto L M, Kipnis A (2014). Role of fused Mycobacterium tuberculosis immunogens and adjuvants in modern Tuberculosis vaccines. Front Immunol, 5: 188

PMID

11 Li Q, Yu H, Zhang Y, Wang B, Jiang W, Da Z, Xian Q, Wang Y, Liu X, Zhu B (2011). Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice. S cand J Immunol, 73(6): 568–576

PMID

12 Liang J, Teng X, Yuan X, Zhang Y, Shi C, Yue T, Zhou L, Li J, Fan X (2015). Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis. MolImmunol, 66(2): 392–401

PMID

13 Lin M Y, Geluk A, Smith S G, Stewart A L, Friggen A H, Franken K L, Verduyn M J, van Meijgaarden K E, Voskuil M I, Dockrell H M, Huygen K, Ottenhoff T H, Klein M R (2007). Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. I nfect Immun, 75(7): 3523–3530

PMID

14 Marongiu L, Donini M, Toffali L, Zenaro E, Dusi S (2013). ESAT-6 and HspX improve the effectiveness of BCG to induce human dendritic cells-dependent Th1 and NK cells activation. PLoS One, 8(10): e75684

PMID

15 Mir F A, Kaufmann S H, Eddine A N (2009). A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire. Clin Vaccine Immunol, 16(10): 1467–1475

PMID

16 Mosavat A, Soleimanpour S, Farsiani H, Sadeghian H, Ghazvini K, Sankian M, Jamehdar S A, Rezaee S A (2016). Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine. Infect Genet Evol, 39: 163–172

PMID

17 Niu H, Hu L, Li Q, Da Z, Wang B, Tang K, Xin Q, Yu H, Zhang Y, Wang Y, Ma X, Zhu B (2011). Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Vaccine, 29(51): 9451–9458

PMID

18 Niu H, Peng J, Bai C, Liu X, Hu L, Luo Y, Wang B, Zhang Y, Chen J, Yu H, Xian Q, Zhu B (2015). Multi-Stage Tuberculosis Subunit Vaccine Candidate LT69 Provides High Protection against Mycobacterium tuberculosis Infection in Mice. PLoS One, 10(6): e0130641

PMID

19 O’Garra A, Redford P S, McNab F W, Bloom C I, Wilkinson R J, Berry M P (2013). The immune response in tuberculosis. Annu Rev Immunol, 31(1): 475–527

PMID

20 Shi C, Chen L, Chen Z, Zhang Y, Zhou Z, Lu J, Fu R, Wang C, Fang Z, Fan X (2010). Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein. Vaccine, 28(32): 5237–5244

PMID

21 Silva B D, Tannus-Silva D G, Rabahi M F, Kipnis A, Junqueira-Kipnis A P (2014). The use of Mycobacterium tuberculosisHspX and GlcB proteins to identify latent tuberculosis in rheumatoid arthritis patients. Mem Inst Oswaldo Cruz, 109(1): 29–37

PMID

22 Soleimanpour S, Farsiani H, Mosavat A, Ghazvini K, Eydgahi M R, Sankian M, Sadeghian H, Meshkat Z, Rezaee S A (2015). APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice. ApplMicrobiol Biotechnol, 99(24): 10467–10480

PMID

23 Taylor J L, Wieczorek A, Keyser A R, Grover A, Flinkstrom R, Karls R K, Bielefeldt-Ohmann H, Dobos K M, Izzo A A (2012). HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule. Immunol Cell Biol, 90(10): 945–954

PMID

24 Trentini M M, de Oliveira F M, Gaeti M P, Batista A C, Lima E M, Kipnis A, Junqueira-Kipnis A P (2014). Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection. Vaccine, 32(34): 4324–4332

PMID

25 Wang X, Zhang J, Liang J, Zhang Y, Teng X, Yuan X, Fan X (2015). Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-g+ IL-2+ CD4+ and IFN-g+ CD8+ T cells. PLoS One, 10(3): e0122560

PMID

26 Xin Q, Niu H, Li Z, Zhang G, Hu L, Wang B, Li J, Yu H, Liu W, Wang Y, Da Z, Li R, Xian Q, Wang Y, Zhang Y, Jing T, Ma X, Zhu B (2013). Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice. PLoS One, 8(8): e72745

PMID

27 Yuan W, Dong N, Zhang L, Liu J, Lin S, Xiang Z, Qiao H, Tong W, Qin C (2012). Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice. Vaccine, 30(14): 2490–2497

PMID

28 Yuan X, Teng X, Jing Y, M a J, Tian M, Yu Q, Zhou L, Wang R, Wang W, Li L, Fan X (2015). A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection. Appl Microbiol Biotechnol, 99(24): 10587–10595

PMID